Physician profile
Henry Chang
NPI 1740430289
$4,554.49
in general payments reported to CMS, 2019-2025
25 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $336 · 2021: $347 · 2022: $388 · 2023: $677 · 2024: $918 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Travel and Lodging: $76.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.51 |
| Travel and Lodging | $76.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,356.48 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $849.41 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $647.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $275.98 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.86 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $144.31 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Cochlear Americas | $138.98 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Bayer Healthcare Pharmaceuticals INC. | $126.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $100.86 | 2022-2023 | |
| Insmed, INC. | $79.99 | 2021 | |
| Inspire Medical Systems, INC. | $76.56 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $72.91 | 2019-2022 | |
| Radius Health, INC. | $67.72 | 2022-2025 | |
| Exact Sciences Corporation | $49.96 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $44.56 | 2023-2024 | Xtandi, Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $37.17 | 2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $33.30 | 2025 | |
| Corcept Therapeutics | $30.94 | 2025 | Korlym |
| Sobi, INC | $29.67 | 2025 | |
| Pfizer INC. | $28.93 | 2024 | |
| Mallinckrodt Hospital Products INC. | $27.67 | 2021 | |
| Optinose US, INC. | $24.07 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $23.76 | 2019 | |
| Leo Pharma INC. | $20.91 | 2023 | Adbry |
| Gilead Sciences, INC. | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.